-+ 0.00%
-+ 0.00%
-+ 0.00%

Arvinas Plans Preliminary Phase 1 Data Presentation for Lymphoma Drug ARV-393 at ASH 2026

PUBT·11/04/2026 21:09:36
Listen to the news
Arvinas Plans Preliminary Phase 1 Data Presentation for Lymphoma Drug ARV-393 at ASH 2026
  • Arvinas will present preliminary Phase 1 results for ARV-393 (zaloblideg) at the American Society of Hematology meeting on December 14, 2026.
  • The trial evaluates the oral BCL6 degrader in patients with relapsed or refractory non-Hodgkin lymphoma.
  • The presentation will cover safety and drug activity across patients, with preliminary efficacy findings in T-cell lymphomas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041601PRIMZONEFULLFEED9870461) on November 04, 2026, and is solely responsible for the information contained therein.